Non classé

Home/Posts/Non classé
21 05, 2020

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

By |2020-11-18T17:19:35+01:00May 21, 2020|

Nature. 2020 May;581(7808):310-315. doi: 10.1038/s41586-020-2269-x.
Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans.

4 05, 2020

AhR activation defends gut barrier integrity against damage occurring in obesity

By |2020-11-18T16:33:39+01:00May 4, 2020|

Mol Metab. 2020 Sep;39:101007. doi: 10.1016/j.molmet.2020.101007. Epub 2020 Apr 28.
Obesity is characterized by systemic and low-grade tissue inflammation. In the intestine, alteration of the intestinal barrier and accumulation of inflammatory cells in the epithelium are important contributors of gut inflammation...

21 04, 2020

Comparative Study of PPARγ Targets in Human Extravillous and Villous Cytotrophoblasts

By |2020-11-18T16:00:53+01:00April 21, 2020|

PPAR Res. 2020 Apr 1;2020:9210748. doi: 10.1155/2020/9210748. eCollection 2020.
Trophoblasts, as the cells that make up the main part of the placenta, undergo cell differentiation processes such as invasion, migration, and fusion.

17 04, 2020

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort

By |2020-11-18T17:12:03+01:00April 17, 2020|

J Hepatol. 2020 Sep;73(3):505-515. doi: 10.1016/j.jhep.2020.04.003.
Genetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most genome-wide association studies...

11 03, 2020

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders

By |2020-11-18T17:28:20+01:00March 11, 2020|

Nat Rev Gastroenterol Hepatol. 2020 May;17(5):279-297. doi: 10.1038/s41575-020-0269-9.
Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease (NAFLD).

4 03, 2020

Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis

By |2020-11-18T16:42:00+01:00March 4, 2020|

Sci Rep. 2020 Mar 2;10(1):3850. doi: 10.1038/s41598-020-60615-0.
Hepatic fibrosis is a major consequence of chronic liver disease such as non-alcoholic steatohepatitis which is undergoing a dramatic evolution given the obesity progression worldwide, and has no treatment to date...

30 01, 2020

Autophagy inhibition blunts PDGFRA adipose progenitors’ cell-autonomous fibrogenic response to high-fat diet

By |2020-11-18T16:56:00+01:00January 30, 2020|

Autophagy. 2020 Jan 28:1-11. doi: 10.1080/15548627.2020.1717129.
Adipose tissue (AT) fibrosis in obesity compromises adipocyte functions and responses to intervention-induced weight loss...

25 01, 2020

Gut Microbiota Profile of Obese Diabetic Women Submitted to Roux-en-Y Gastric Bypass and Its Association with Food Intake and Postoperative Diabetes Remission

By |2020-11-18T16:28:40+01:00January 25, 2020|

Nutrients. 2020 Jan 21;12(2):278. doi: 10.3390/nu12020278.
Gut microbiota composition is influenced by environmental factors and has been shown to impact body metabolism. Objective: To assess the gut microbiota profile before and after Roux-en-Y gastric bypass (RYGB) and the correlation with food intake and postoperative type 2 diabetes remission (T2Dr)...

17 01, 2020

OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions

By |2020-11-18T16:39:02+01:00January 17, 2020|

Obes Facts. 2020;13(1):1-28. doi: 10.1159/000505342. Epub 2020 Jan 16.
Heterogeneity of interindividual and intraindividual responses to interventions is often observed in randomized, controlled trials for obesity. To address the global epidemic...

16 10, 2019

Gut microbiota of obese subjects with Prader-Willi syndrome is linked to metabolic health

By |2020-11-18T17:25:18+01:00October 16, 2019|

Gut. 2020 Jul;69(7):1229-1238. doi: 10.1136/gutjnl-2019-319322.
The gut microbiota has been implicated in the aetiology of obesity and associated comorbidities. Patients with Prader-Willi syndrome (PWS) are obese but partly protected against insulin resistance...

11 04, 2019

Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity

By |2019-05-21T17:29:42+02:00April 11, 2019|

FASEB J. 2019 Apr;33(4):4741-4754
Lipidomic techniques can improve our understanding of complex lipid interactions that regulate metabolic diseases. Here, a serum phospholipidomics ...

1 04, 2019

Synergistic convergence of microbiota-specific systemic IgG and secretory IgA

By |2019-05-21T17:29:01+02:00April 1, 2019|

J. Allergy Clin. Immunol. 2019 Apr;143(4):1575-1585.e4
BACKGROUND: Commensals induce local IgA responses essential to the induction of tolerance to gut microbiota, but it remains unclea...

30 03, 2019

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

By |2019-05-21T17:32:38+02:00March 30, 2019|

BMJ Open 2019 Mar;9(3):e017995
OBJECTIVE: To systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes...

Go to Top